Generics - Hospira

Filter

Current filters:

Hospira

Popular Filters

Global oncology biosimilars market 2014-2018

28-11-2014

The global oncology biosimilars market is expected to expand at a compound annual growth rate (CAGR)…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingMylanSandoz

Hospira warned by FDA over Australian manufacturing facility

Hospira warned by FDA over Australian manufacturing facility

02-10-2014

USA-based injectable generic drugs specialist Hospira revealed in a filing with the US Securities and…

AustraliaGenericsHospiraProductionRegulationUSA

Hospira’s Retacrit effective in chemotherapy-induced anemia

Hospira’s Retacrit effective in chemotherapy-induced anemia

24-07-2014

USA-based Hospira, a leading provider of generic injectable drugs and infusion technologies, announced…

BiosimilarsErythropoiesis-stimulating agentsGenericsHematologyHospiraInfusion technologiesResearchRetacritUSA

Hospira completes buy of Orchid's API production and R&D facility

Hospira completes buy of Orchid's API production and R&D facility

06-07-2014

US provider of injectable drugs and infusion technologies Hospira says it has completed the acquisition…

GenericsHospiraIndiaMergers & AcquisitionsOrchid Chemicals & PharmaceuticalsProduction

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage

08-06-2014

The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Global biosimilar drug revenues will reach $2,445 million in 2013, says Visiongain

08-05-2013

The world market for biosimilar drugs will be worth $2,445 million in 2013, growing by more than 20%…

BiotechnologyCellTrionGenericsGlobalHospiraMarkets & MarketingSandoz

Hospira returns to profit, with EPS beating expectations

08-11-2012

USA-based Hospira (NYSE: HSP), a global leader in injectable drugs and infusion technologies, reported…

FinancialGenericsHospira

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

Hospira to acquire Orchid API production and R&D facility

30-08-2012

US injectable generic drugs specialist Hospira (NYSE: HSP) has reached an agreement to acquire an active…

GenericsHospiraMarkets & MarketingOrchid Chemicals & PharmaceuticalsProductionResearch

Hospira recalls hydromorphone pain product on overdose concerns

20-08-2012

USA-based Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies,…

GenericsHospirahydromorphone injectionMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Hospira 2nd-qtr income falls 45%, hit by costs

02-08-2012

USA-based Hospira (NYSE: HSP), a leading provider of injectable drugs and infusion technologies, reported…

FinancialGenericsHospira

Fitch backs FDA planned guidelines, saying they open the door to biosimilars

12-02-2012

Fitch Ratings believes the US Federal Drug and Administration's proposed biosimilar pathway regulations,…

BiotechnologyGenericsHospiraNorth AmericaRegulation

Hospira challenges Cubist patents on Cubicin

10-02-2012

US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

Hospira progresses biosimilar Epogen

11-01-2012

USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

Back to top